Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 231

1.

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

D'Amico AV, Chen MH, Roehl KA, Catalona WJ.

N Engl J Med. 2004 Jul 8;351(2):125-35.

PMID:
15247353
[PubMed - indexed for MEDLINE]
Free Article
2.

Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.

Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR.

J Urol. 2003 Jan;169(1):157-63.

PMID:
12478126
[PubMed - indexed for MEDLINE]
3.

Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.

Bissonette EA, Fulmer BR, Petroni GR, Moul JW, Theodorescu D.

J Urol. 2001 Oct;166(4):1328-31; discussion 1331-2.

PMID:
11547067
[PubMed - indexed for MEDLINE]
4.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
[PubMed - indexed for MEDLINE]
5.

Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.

D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ.

J Urol. 2006 Dec;176(6 Pt 2):S11-5.

PMID:
17084157
[PubMed - indexed for MEDLINE]
6.

Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.

Kupelian P, Katcher J, Levin H, Zippe C, Klein E.

Urology. 1996 Aug;48(2):249-60.

PMID:
8753737
[PubMed - indexed for MEDLINE]
8.

Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.

Grossfeld GD, Latini DM, Lubeck DP, Broering JM, Li YP, Mehta SS, Carroll PR.

Urology. 2002 Apr;59(4):560-5.

PMID:
11927314
[PubMed - indexed for MEDLINE]
9.

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.

Pound CR, Partin AW, Epstein JI, Walsh PC.

Urol Clin North Am. 1997 May;24(2):395-406.

PMID:
9126237
[PubMed - indexed for MEDLINE]
10.

Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.

Zhou M, Hayasaka S, Taylor JM, Shah R, Proverbs-Singh T, Manley S, Rubin MA.

J Urol. 2001 Dec;166(6):2193-7.

PMID:
11696734
[PubMed - indexed for MEDLINE]
11.

Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy.

Nelson CP, Rubin MA, Strawderman M, Montie JE, Sanda MG.

Urology. 2002 May;59(5):740-5; discussion 745-6.

PMID:
11992850
[PubMed - indexed for MEDLINE]
12.

Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.

D'Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW.

Cancer. 2007 Jul 1;110(1):56-61.

PMID:
17530618
[PubMed - indexed for MEDLINE]
Free Article
13.

Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.

Freedland SJ, Csathy GS, Dorey F, Aronson WJ.

Urology. 2002 Jul;60(1):84-8.

PMID:
12100929
[PubMed - indexed for MEDLINE]
14.

Role of radical prostatectomy in patients with prostate cancer of high Gleason score.

Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Sakr W, Grignon D, Wood DP Jr, Pontes JE.

Prostate. 1999 Apr 1;39(1):60-6.

PMID:
10221268
[PubMed - indexed for MEDLINE]
15.

Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.

Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ.

J Urol. 2002 Jul;168(1):110-5.

PMID:
12050502
[PubMed - indexed for MEDLINE]
16.

Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer.

D'Amico AV, Whittington R, Malkowicz B, Schnall M, Schultz D, Cote K, Tomaszewski JE, Wein A.

J Urol. 2000 Sep;164(3 Pt 1):759-63.

PMID:
10953141
[PubMed - indexed for MEDLINE]
17.

Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.

Gonzalez CM, Roehl KA, Antenor JV, Blunt LW, Han M, Catalona WJ.

Urology. 2004 Oct;64(4):723-8.

PMID:
15491709
[PubMed - indexed for MEDLINE]
18.

Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer.

Beyer DC, Thomas T, Hilbe J, Swenson V.

Brachytherapy. 2003;2(2):77-84.

PMID:
15062144
[PubMed - indexed for MEDLINE]
19.

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.

Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC.

J Urol. 2003 Feb;169(2):517-23.

PMID:
12544300
[PubMed - indexed for MEDLINE]
20.

The relationship between preoperative prostate-specific antigen and biopsy Gleason sum in men undergoing radical retropubic prostatectomy: a novel assessment of traditional predictors of outcome.

Pierorazio P, Desai M, McCann T, Benson M, McKiernan J.

BJU Int. 2009 Jan;103(1):38-42. doi: 10.1111/j.1464-410X.2008.07952.x. Epub 2008 Sep 3.

PMID:
18778352
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk